Objective-Carriers of the PCSK9 (proprotein convertase subtilisin/kexin 9) R46L genetic variant (rs11591147) are characterized by low levels of low-density lipoprotein cholesterol and a decreased risk of cardiovascular disease. We studied the impact of the R46L variant on lipoprotein size and composition. Approach and Results-Lipoprotein size and composition were measured by nuclear magnetic resonance spectroscopy in 2373 participants of the EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk study. 
Introduction
PCSK9 (proprotein convertase subtilisin/kexin 9) is a key player in low-density lipoprotein (LDL) metabolism, 1 and a common loss-of-function R46L variant (rs11591147) is associated with both low LDL cholesterol (LDL-C) levels and low risk of cardiovascular disease (CVD). 2 Whether this variant is also associated with other potential CVD risk factors such as measures of plasma lipoprotein subfractions obtained by nuclear magnetic resonance (NMR) spectroscopy is unknown. We hypothesized that carriers of the R46L are characterized by a specific antiatherogenic lipoproteinlipid profile measured by NMR spectroscopy compared with noncarriers. We tested these hypotheses in participants of the EPIC (European Prospective Investigation of Cancer)-Norfolk study.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
This analysis comprised 3821 EPIC-Norfolk participants, previously included in a nested case-control substudy. 3 A total of 2174 were incident CVD cases, and 1647 were controls, whereas 3700 were noncarriers and 121 were heterozygous carriers of the PCSK9 R46L variant. No homozygous carriers were included. NMR spectroscopy data were available for 2296 noncarriers and 77 carriers, and the clinical characteristics of these participants are presented in Table 1 . As expected, total cholesterol and LDL-C levels were significantly lower in carriers compared with noncarriers. The heterozygous carriers showed a trend toward a lower CVD risk with an odds ratio (95% confidence interval) of 0.72 (0.50-1.04). Because this cohort was age and sex matched, the ageand sex-adjusted odds ratios were identical. We measured serum levels of cholesteryl ester transfer protein; lecithin-cholesterol acyltransferase; lipoprotein lipase; oxidized phospholipids; lipoprotein(a) [Lp(a)]; C-reactive protein; apolipoproteins A-I, A-II, A-V, and B; and NMRmeasured lipoproteins (Table 2) . Cholesteryl ester transfer protein, lecithin-cholesterol acyltransferase, lipoprotein lipase, oxidized phospholipids, C-reactive protein, apolipoprotein A-I, apolipoprotein A-II, and high-density lipoprotein particle levels, as well as high-density lipoprotein size, LDL size, and very low-density lipoprotein (VLDL) size were not different in carriers compared with noncarriers. Apolipoprotein B; Lp(a); VLDL-P (total, medium, and small); intermediate-density lipoprotein particles (IDL-P); and LDL particle (LDL-P) levels; and secretory phospholipase A2 and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity were lower in carriers compared with noncarriers.
Discussion
Our study shows that carriers of the PCSK9 R46L variant are characterized by lower levels of NMR-measured atherogenic lipoproteins and subfractions compared with noncarriers. The most prominent differences based on percentage change between carriers and noncarriers were observed with IDL-P (−18%) and medium VLDL-P (−16%; Figure) . The most prominent differences based on change in SD between carriers and noncarriers were observed with apolipoprotein B (−0.44 SD), LDL-C (−0.41 SD), VLDL-P (−0.40 SD), and LDL-P (−0.40 SD). Our results extend those of Cohen et al, 2 who have reported a 15% reduction in LDL-C in carriers of the PCSK9 R46L variant in the ARIC study (Atherosclerosis Risk in Communities). The effect on other parameters of the lipoprotein-lipid profile was comparable, with in both studies significant lower levels of total cholesterol and no effect on high-density lipoprotein cholesterol.
In a cross-sectional study of 52 healthy subjects, PCSK9 levels were found to correlate with total cholesterol, nonhigh-density lipoprotein cholesterol, LDL-C, triglycerides, and VLDL-P and LDL-P concentrations. 4 In a subsequent multivariable regression analysis, PCSK9 levels were only related to LDL-P concentration. Interestingly, in an analysis that included the 3 LDL subfractions, PCSK9 was only associated with IDL-P. The R46L variant examined in our study has been shown to be associated with lower levels of PCSK9, 5 and therefore, we expected a similar effect on NMR lipoprotein subfractions. Our study suggests that there is not only an association between PCSK9 and IDL-P but also with other lipoprotein particles. The effect of the R46L variant on lipoproteins in our study seemed to be comparable with the results of Chasman et al, 6 who showed a significant effect of the single-nucleotide polymorphism on large LDL-P, total LDL-P, small LDL-P, IDL-P, LDL-C, total VLDL-P, and small VLDL-P. Other groups also documented the effect of different single-nucleotide The baseline characteristics were based on variables from participants whose NMR data were available. Data are presented as mean±SD and percentage number for categorical variables. HDL indicates high-density lipoprotein; LDL, low-density lipoprotein; and NMR, nuclear magnetic resonance.
polymorphisms at the PCSK9 locus on plasma lipids. 7, 8 A recent analysis of the Copenhagen general population study showed that carriers of the R46L variant had lower Lp(a) than noncarriers. 9 Recently, Koren et al 10 documented the impact of the PCSK9 inhibitor alirocumab on NMR lipoprotein subfractions in 60 patients with hypercholesterolemia. Alirocumab therapy resulted in a 63.3% decrease of LDL-P concentration, whereas IDL-P concentration fell by 52.8%. Although the effect of alirocumab on Lp(a) was not determined by Koren et al, 10 Lp(a) reductions ≤30% were demonstrated in phase 2 trials. 11 The effect of alirocumab on cholesteryl ester transfer, lecithin-cholesterol acyltransferase, lipoprotein lipase, oxidized phospholipids, sPLA2, and Lp-PLA2 has not been reported. Our study extends the results of Koren et al by showing that PCSK9 inhibition could be associated with lower LDL-P and Lp(a) in patients without hypercholesterolemia. 10 The relationship between LDL-C and CVD risk is strong and consistent, but evidence suggest that LDL-P concentrations could be more closely associated with CVD risk than LDL-C. 12 Because of a possible discordance between LDL-C and LDL-P concentrations, patients with LDL-C levels on target could be at increased CVD risk attributable to high LDL-P levels. 13 The American Association of Clinical Chemistry has suggested to strive for a LDL-P concentration treatment goal of <1100 nmol/L 14 or an equivalent LDL-C level of <100 mg/dL in patients at high CVD risk according to the National Cholesterol Education Program Adult Treatment Panel III. 15 As was shown by Ference et al, 16 a lifelong exposition to lower LDL-C levels resulted in a 3-fold greater reduction in CHD per millimoles per liter than in the statin trials. Also, it was recently shown that plasma Lp-PLA2 are inversely correlated with PCSK9 levels. 17 This enzyme is positively associated with the development of CHD, stroke, and aortic stenosis.
18,19 R46L carriers had both lower levels of secretory phospholipase A2 and Lp-PLA2 than noncarriers, which could be an additional explanation of the lower CHD risk in R46L carriers. Results of our genetic association study are, however, more likely to imply a causal role for PCSK9 in Lp-PLA2 than an association between blood levels of both factors based on correlations.
In conclusion, our results suggest that carriers of the PCSK9 R46L genetic variant have a lifelong lower exposure to all atherogenic lipoproteins, including Lp(a), secretory phospholipase A2, and Lp-PLA2, which presumably explains their reduced CHD risk.
